Related Experiment Video
Updated: Aug 15, 2026
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine
Kim P C Kuypers1, Jan G Ramaekers
1Experimental Psychopharmacology Unit, Department of Neurocognition, Faculty of Psychology, Maastricht University, Maastricht, the Netherlands. k.kuypers@psychology.unimaas.nl
Abstract:
A range of studies has indicated that users of 3.4-Methylene-dioxymethamphetamine (MDMA, 'Ecstasy') display cognitive deficits, particularly memory impairment, as compared to non-drug using controls. Yet it is difficult to determine whether these deficits are caused by MDMA or some other confounding factor, such as polydrug use. The present study was designed to establish the direct relation between MDMA and memory impairment under placebo-controlled conditions. Eighteen recreational MDMA users participated in a double blind, placebo controlled, 3-way crossover design. They were treated with placebo, MDMA 75mg and methylphenidate 20mg. Memory tests were conducted between 1.5-2h (intoxication phase) and between 25.5-26h (withdrawal phase) post dosing. Results showed that a single dose of MDMA caused impairment of immediate and delayed recall on a verbal learning task during the intoxication phase. However, there was no residual memory impairment during the withdrawal phase. Subjects reported more fatigue and less vigour, but no symptoms of depression during the withdrawal phase of MDMA treatment. Methylphenidate did not affect memory or mood at any time of testing. A single dose of MDMA produces transient memory impairment.
Insights
A single dose of 3.4-Methylene-dioxymethamphetamine (MDMA, "Ecstasy") causes temporary memory impairment in recreational users. This cognitive deficit, specifically in recall, is evident during intoxication but absent during withdrawal.
Area of Science:
- Neuroscience
- Psychopharmacology
- Cognitive Psychology
Background:
- Previous studies suggest cognitive deficits, especially memory impairment, in 3.4-Methylene-dioxymethamphetamine (MDMA, "Ecstasy") users.
- Confounding factors like polydrug use make it challenging to isolate MDMA's direct effects on cognition.
Purpose of the Study:
- To investigate the direct relationship between MDMA administration and memory impairment.
- To differentiate MDMA's effects from other potential confounding variables under controlled conditions.
Main Methods:
- A double-blind, placebo-controlled, 3-way crossover study involving 18 recreational MDMA users.
- Participants received placebo, MDMA (75mg), and methylphenidate (20mg) in separate sessions.
- Memory and mood assessments were conducted during intoxication (1.5-2h) and withdrawal (25.5-26h) phases.
Main Results:
- A single 75mg dose of MDMA significantly impaired immediate and delayed verbal recall during the intoxication phase.
- No residual memory impairment was observed during the withdrawal phase post-MDMA administration.
- Methylphenidate did not impact memory or mood during any testing phase.
Conclusions:
- MDMA administration leads to transient memory impairment, primarily affecting verbal recall during the acute intoxication period.
- The memory deficits associated with MDMA are temporary and do not persist into the withdrawal phase.
- Methylphenidate showed no significant effects on memory or mood in this study context.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:29Hepatic Encephalopathy
01:13Amnesia
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...